Europe
Variant Prioritization Tool Driven by World’s Largest Curated Mutation Database
Proceeds will facilitate clinical development of Imcyse’s technology in type 1 diabetes, multiple sclerosis and other indications
Vivoryon Therapeutics AG and goetzpartners, announced their collaboration to explore the expansion of Vivoryon’s proprietary platform based on its Glutaminyl-peptide cyclotransferase-like protein technology into the field of immuno-oncology.
Amgen hopes the data will provide insights into specific diseases that will help develop new drugs.
Google and Sanofi are partnering to set up a new virtual innovation lab with a focus on data technologies and digital health. The goal is to change how Sanofi develops new drugs.
Rozlytrek is the first tumor-agnostic medicine approved in Japan for adult and pediatric patients with NTRK fusion-positive advanced recurrent solid tumors.
The approval marks the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for children and adolescents with type 2 diabetes.
Galapagos NV received a transparency notification from The Capital Group Companies, Inc.
Minimally-invasive blood test could complement colonoscopy in high-risk LS patients who are non-compliant with colonoscopy screening recommendations or may develop precancerous lesions in the interval between colonoscopies
Medigene AG announced that clinical data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia was presented during the annual congress of the European Hematology Association taking place from 13 - 16 June in Amsterdam.
PRESS RELEASES